Genmab’s bispecific halves risk of death in first-line HNSCC
Genmab’s petosemtamab, an investigational IgG1-bispecific antibody, plus Keytruda (pembrolizumab) reduced the risk of death by 50% in a Phase III…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Podcast: ESMO26: Major readouts from the 2026 congress
This year's European Society of Medical Oncology (ESMO) Congress has come to a close, with hundreds of studies having been…
-
Lilly’s retatrutide beats Ozempic in head-to-head trial
Eli Lilly, a dominant force in the obesity and type 2 diabetes market, has just beaten its biggest rival, with…
-
ESMO26: US and FDA movements to improve oncology trials a positive signal
Since the Trump Administration took office in the White House, there has been an uptick in the number of guidance…
-
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
Arguably the most impactful readout in skin cancer in recent months was MSD and Moderna’s melanoma cancer vaccine data. At…
-
ESMO26: Breast cancer treatment landscape continues to be redefined
Breast cancer is the most common cancer among women globally, accounting for roughly 25% of all female cancer diagnoses; however,…
-
ESMO26: Combination therapies show promise in prostate cancer
Prostate cancer is the most diagnosed cancer in men worldwide, but little is known about why some cancers are slow-growing,…
-
ESMO26: Novel combo successes signal shift from frontline chemo in cold cancers
The past few years have seen a number of revolutionary modalities join the oncology landscape, such as antibody-drug conjugates (ADCs),…
-
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape
Pancreatic cancer has historically presented a poor clinical outlook, offering patients few effective therapeutic options. Because the disease rarely causes…
-
ESMO26: MSD and Moderna drop cancer vaccine trial data early
MSD and Moderna have reported full Phase III results for their personalised cancer vaccine, but both companies’ shares fell after…